Insider Trading March 25, 2026

Cryoport CSO Sells $10,969 in Stock to Cover Tax Liability After RSU Vesting

Mark W. Sawicki disposed of 1,341 shares on March 23, 2026; company posts revenue beat but EPS miss in Q4 2025

By Leila Farooq CYRX
Cryoport CSO Sells $10,969 in Stock to Cover Tax Liability After RSU Vesting
CYRX

Cryoport Inc. (NASDAQ: CYRX) Chief Scientific Officer Mark W. Sawicki sold 1,341 shares of the company's common stock on March 23, 2026 for $8.18 per share, a transaction totaling $10,969. The sale was carried out to satisfy tax obligations tied to the vesting of restricted stock rights, according to the company's policies. After the disposition, Sawicki holds 102,356 shares. Cryoport's shares trade at $8.41 with a market capitalization of $417.79 million. The company reported fourth-quarter 2025 revenue above expectations but missed on EPS, and an InvestingPro Fair Value assessment flags the stock as overvalued at current levels.

Key Points

  • Cryoport Chief Scientific Officer Mark W. Sawicki sold 1,341 shares on March 23, 2026 at $8.18 per share, totaling $10,969.
  • The sale was executed to meet tax obligations tied to the vesting of restricted stock rights; Sawicki owns 102,356 shares after the transaction.
  • Cryoport reported Q4 2025 revenue of $45.45 million (5.87% above forecast) but missed EPS expectations (-$0.27 vs. -$0.21), and the stock fell in aftermarket trading.

Cryoport Inc. (NASDAQ: CYRX) disclosed that Chief Scientific Officer Mark W. Sawicki sold 1,341 shares of common stock on March 23, 2026, a Form 4 filing with the Securities and Exchange Commission shows. The shares were transacted at $8.18 apiece, producing a total sale amount of $10,969.

Following the sale, Sawicki retains direct ownership of 102,356 shares of Cryoport. The company states the disposition was executed to satisfy tax obligations stemming from the vesting of restricted stock rights, in line with issuer policies governing such events.

At the time of reporting, Cryoport's stock trades at $8.41 and the company carries a market capitalization of $417.79 million.


Recent operational and market context

Cryoport reported fourth-quarter 2025 revenue of $45.45 million, exceeding the $42.93 million that analysts had expected. That revenue result represents a positive surprise of 5.87% relative to forecasted sales. However, the company's earnings per share for the quarter fell short of consensus estimates, at -$0.27 versus an expected -$0.21, constituting a 28.57% miss. Despite the top-line beat, the stock declined in aftermarket trading following the release.

An InvestingPro Fair Value assessment cited in available research indicates Cryoport appears overvalued at its current trading level. The InvestingPro platform also provides a Pro Research Report on CYRX as part of its broader coverage of U.S. equities.


What the filing shows

  • Insider: Mark W. Sawicki, Chief Scientific Officer
  • Date of transaction: March 23, 2026
  • Shares sold: 1,341
  • Sale price per share: $8.18
  • Total transaction value: $10,969
  • Shares owned after sale: 102,356
  • Reason provided: to cover tax obligations arising from vesting of restricted stock rights

The facts in the filing and the company’s quarterly results together sketch a mixed picture: a modest insider sale conducted for tax purposes and an earnings release that combined a revenue beat with an EPS shortfall, followed by a negative aftermarket reaction and a valuation note from InvestingPro.

Risks

  • Valuation risk - InvestingPro's Fair Value assessment indicates Cryoport may be overvalued at current market levels, which could affect investor sentiment in the biotech/healthcare and small-cap equity markets.
  • Earnings performance risk - The company’s Q4 2025 EPS missed consensus estimates by 28.57%, a shortfall that coincided with a decline in aftermarket trading and may pressure near-term stock performance.
  • Insider selling context - Although the disclosed sale was to satisfy tax obligations from restricted stock vesting, insider dispositions can introduce uncertainty for investors monitoring insider activity in the healthcare and capital markets sectors.

More from Insider Trading

Photronics Director Disposes $390,000 in Stock; Shares Trade Near Yearly High Mar 25, 2026 SentinelOne President Sells $433K in Stock as Company Announces Leadership and Partnership Moves Mar 25, 2026 SentinelOne Interim CFO Sells 32,221 Shares for About $430,794 as Stock Trades Near $13.36 Mar 25, 2026 SentinelOne CEO Sells Nearly $970k in Stock to Satisfy RSU Tax Withholding Mar 25, 2026 SentinelOne Legal Chief Transfers Shares to Cover RSU Taxes as Company Boosts Leadership and Partnerships Mar 25, 2026